On Chemball
My Chemball
+86-571-8627 3270
Zhongfu Pharmaceutical Co., Ltd.
Zhongfu Pharmaceutical Co., Ltd.
Main Products:
Captopril
ABOUT US
Zhongfu Pharmaceutical Co., Ltd mainly manufactures small volume water injections, powder for injections, tablets & capsules and APIs. The capacity is: 100 million of small volume water injections, 180 million of powder injections, one billion of tablets and capsules and 140 tons of APIs.
The QC department is equipped with modern analytical instruments which can fully satisfy the analysis requirements to APIs, raw materials, chemical intermediates and R&D use. We set up perfect quality assurance system and quality control in every procedure which assure the quality of products.
All of the facilities are GMP approved, operating with cGMP. Especially, among them, the Captopril API workshop was approved by US FDA in 1998 and passed the re-inspection of US FDA in 2004 with ZERO 483, we got COS certificate in 2007.
We have set up business relationships with foreign partners for APIs including Captopril, Lisinopril, Hydralazine Hydrochloride etc. as well as finished dosage forms. We hold the DMF with CTD format for Lisinopril, Gemfibrozil and Hydralazine HCl; several finished dosage form including water injectable, power injection and oral dosage have been registered in EU and Africa and entered into the commercial supplying from 2007 going on.
Basic Information
Tax ID
913707037232674976
Country/Region
Shandong, China
Year Established
1966
Registered Capital
CNY 78.4 Million
Business Type
CRO
Total Employees
100-500 people
Quality Management Certificate
other,
US-FDA,
CEP/COS
Total Annual Revenue
-
Enterprise Ownership
Private Owned
Is This Your Own Factory
Yes
Summary Up
Lamivudine, an anti hepatitis B and AIDS drug, is the only product that has real intellectual property rights in China (two synthetic patents)
PLANT LOCATION
COMPANY ALBUM
CERTIFICATES